Hemogenic Endothelium Differentiation from Human Pluripotent Stem Cells in A Feeder- and Xeno-free Defined Condition

Summary

Here, we present a protocol to precisely form hemogenic endothelium from human pluripotent stem cells in a feeder- and xeno-free condition. This method will have broad applications in disease modeling and screening for therapeutic compounds.

Abstract

Deriving functional hematopoietic stem and progenitor cells (HSPCs) from human pluripotent stem cells (PSCs) have been an elusive goal for autologous transplants to treat hematological and malignant disorders. Hemogenic endothelium (HE) is an amenable platform to produce functional HSPCs by transcription factors or to induce lymphocytes in a robust manner. However, current methods to derive HE are either costly or variable in yield. In this protocol, we established a cost-effective and precise method to derive HE within 4 days in a feeder- and xeno-free defined condition. The resultant HE underwent an endothelial-to-hematopoietic transition and produced CD34⁺CD45⁺ clonogenic hematopoietic progenitors. The potential capacity of our platform for generating functional HSPCs will have broad applications in disease modeling and screening for therapeutic compounds.

Introduction

The development of new therapeutics for hematological and immunological disorders has been hampered by the lack of robust platforms for disease modeling and high throughput drug screening with autologous hematopoietic stem cells (HSCs) derived from patient pluripotent stem cells (PSCs). The breakthrough of induced (i)PSC technology holds promise to model diseases from patients' cells, but the establishment of functional HSCs from patient iPSCs has been elusive. In order to derive HSCs from human PSCs, the proper induction of embryonic patterning and transcriptional programs is key^{1,2,3,4,5,6,7,8}. Recent progress in hematopoietic development has demonstrated the role of hemogenic endothelium (HE) in HSC development⁹. HE can be induced from PSCs and is amenable to downstream intervention such as gene transfer^10,11,12,13. Using HE as a platform, the combination of 5 transcription factors (ERG, HOXA5, HOXA9, LCOR, RUNX1) successfully induced functional HSCs that engraft long-term and differentiate into multiple lineages¹⁴. However, variable and inefficient generation of HE from PSCs have hampered the systematic manipulation and analysis of cells along with the off-the-shelf production and large-scale induction of hematopoietic cells for clinical use.

Here, we describe a cost-effective and precise method to derive HE in 4 days with a feeder- and xeno-free defined condition. In this method, spheroid formation and spontaneous re-flattening on iMarix-511 ensures a consistent density of PSC colonies, which is crucial for the efficient induction of HE cells.

Protocol

1. Reagents

1. Cell lines (human PSCs): obtain either embryonic stem cells (ESCs) or iPSC lines 409B2 and 201B7(317-9)) and CBA11.
2. Reagent preparation
   1. PSC plating medium: mix PSC maintenance medium with 10 µM Y-27632 and store at 4 °C.
   2. PSC Spheroid tiling medium: mix PSC maintenance medium with 625–1,250 ng/mL human recombinant Laminin-511 E8 fragment (LM511-E8)(depending on cell line) just prior to use.
      NOTE: LM511-E8 can be mixed in media¹⁵. Other matrix such as full-length laminin-511 needs to be pre-coated, and even did so, they do not sustain mesodermal organoids adhered during differentiation process.
   3. Day 0 differentiation medium: mix Mesodermal basal medium with 2 µM CHIR99021, 80 ng/mL Bone morphogenetic protein 4 (BMP4) and 80 ng/mL Vascular endothelial growth factor (VEGF).
   4. Day 2 differentiation medium: mix Hemogenic basal medium with 1 µM SB431542, 80 ng/mL VEGF and 100 ng/mL Stem cell factor (SCF).
   5. Prepare phosphate buffer saline (PBS) without calcium or magnesium (See Table of Materials).
   6. 1 mM ethylenediaminetetraacetic acid (EDTA) buffer: add 1 mL of 0.5 M EDTA to 500 mL of PBS.
   7. EHT medium: mix Hematopoietic basal medium with 50 ng/mL SCF, 20 ng/mL thrombopoietin (TPO), 50 ng/mL Fms-related tyrosine kinase 3 ligand (Flt-3L), 20 ng/mL Interleukin-6/Interleukin-6 receptor alpha (IL-6/IL-6Rα), insulin-transferrin-selenium-ethanolamine, L-glutamine and Penicillin/Streptomycin/Amphotericin B.
   8. FACS buffer: mix PBS with 2% fetal calf serum and 1 mM EDTA.
   9. Prepare magnetic separation buffer (See Table of Materials).
   10. Prepare methylcellulose-based media (See Table of Materials).

2. PSC Colony Formation

1. Grow hPSCs to 70 – 80% confluency on a 0.5 µg cm^-2 LM511-E8-coated 6-well plate in mTeSR1 in a 37 °C incubator with 5% CO₂.
2. PSC dissociation (Day -4)
   1. Aspirate the medium and wash the cells with PBS twice. Rinse the cells with dissociation solution. Incubate at 37 °C for 15 min (cells will not desiccate in this time).
   2. Suspend the cells in PSC maintenance medium, transfer the suspension to an appropriately sized tube and centrifuge the cells at 200 x g for 3 min. Aspirate the supernatant and suspend the cells in PSC plating medium.
3. Plate the PSC suspension at a density of 48,000 – 70,000 cells cm^-2 (depending on the cell line) onto a micro-fabricated plastic vessel and incubate overnight in the 37 °C incubator with 5% CO₂.
   NOTE: We recommend 100 μL well^-1 of cell suspension in a 96-well micro-fabricated plastic vessel. You will typically seed 20,000 cells well^-1 in a 96-well plate to yield approximately 100 spheroids.
4. Tiling PSC spheroids on LM511-E8 (Day -3)
   1. Collect the PSC spheroids in a 15 mL conical tube by gently pipetting using P1000 micropipetter and leave the spheroids to stand at room temperature for 2 min to precipitate by gravity. Aspirate the supernatant.
   2. Suspend in spheroid plating medium, dispense the suspension into a non-coated 6-well culture plate at a density of 4-spheroids cm^-2 and culture in the 37 °C incubator with 5% CO₂ for three days.

3. Hemogenic Induction (Day 0)

1. Aspirate the medium, add Day0 differentiation medium and culture in the 37 °C incubator with 5% O₂ and 5% CO₂ (hypoxic incubator).
2. After two days of culture in Day0 differentiation medium, aspirate the medium, then add Day2 differentiation medium and culture in the hypoxic incubator.

4. Isolation of Hemogenic Endothelium (Day 4)

1. Two days later, aspirate the medium and wash the cells with PBS twice. Rinse the cells with dissociation solution. Incubate in the 37 °C incubator with 5% CO₂ for 30 min.
2. Gently suspend the cells in 1 mM EDTA to dissociate to the single-cell level, transfer the suspension into a 50 mL conical tube and centrifuge the cells at 200 x g for 3 min. Aspirate the supernatant and suspend the cell pellet with 300 µL of magnetic separation buffer.
3. Add 100 µL of CD34⁺ microbeads and gently pipet. Incubate for 30 min at room temperature. Up to 20 million cells per 100 μL CD34⁺ beads can be used.
4. Filter the suspension through a 40 µm cell strainer.
5. Separate the CD34⁺ cells using a magnetic separator.

5. Induction of Endothelial-to-hematopoietic Transition (EHT)

1. Fibronectin coating
   1. Prepare the required volume of 5 µg/mL fibronectin-coating solution by diluting 1 mg/mL fibronectin in PBS.
   2. Dispense 0.5 mL of the coating solution into each well of a 24-well culture plate. Incubate the plate at room temperature for 30 min.
2. Centrifuge the sorted CD34⁺ cells at 200 x g for 3 min. Resuspend the cell pellet in 1 mL of EHT medium.
3. Determine the viable cell density with the cell counter. Adjust the cell density to 200,000 cells mL^-1 by adding EHT medium.
4. Aspirate and discard the coating solution from the fibronectin-coated well. Dispense 0.5 mL of CD34⁺ cell suspension into each fibronectin-coated well.
5. Incubate in the hypoxic incubator for one week.

6. Flow Cytometry Analysis of Hematopoietic Cells

1. Floating cell collection: Transfer the culture medium to a 15 mL conical tube. Centrifuge the medium at 200 x g for 3 min. Aspirate the supernatant.
2. Adherent cell collection
   1. Wash the cells with 0.5 mL of PBS twice.
   2. Rinse the cells with dissociating solution and aspirate the surplus liquid.
   3. Incubate the plate in the 37 °C incubator for 5 min.
   4. Resuspend the cells in 1 mL of FACS buffer.
3. Mix the floating cells and adherent cells.
4. Centrifuge the cells at 200 x g for 3 min. Aspirate the supernatant. Resuspend in 50 µL of FACS buffer. Incubate the cells with anti-CD34 and anti-CD45 antibodies for 1 h at room temperature in the dark.
5. Wash the cells with PBS twice and centrifuge at 200 x g for 3 min. Aspirate the supernatant and resuspend in 0.5 mL of FACS buffer with 0.5 µg/mL 4',6-diamidino-2-phenylindole.
6. Measure CD34 and CD45 expression by flow cytometer.

7. Colony Forming Unit (CFU) Assay of Hematopoietic Cells

1. Hematopoietic cell collection: Transfer the medium from the culture to a 15 mL conical tube. Gently rinse the well twice with PBS.
2. Centrifuge the cells at 200 x g for 3 min. Aspirate the supernatant. Resuspend in 1 mL of EHT medium. Determine cell number with the cell counter.
3. Add a suspension volume equivalent of 10,000 cells to 3 mL of methylcellulose-based media supplemented with antibiotics and mix well 5 times with a 16 G or 18 G syringe.
4. Dispense the whole methylcellulose-based media suspension into each well of a 6-well plate.
5. Incubate in the 37 °C incubator with 5% CO₂ for two weeks while keeping moist. Do not disturb the dish. Colonies are motion-sensitive.
6. After two weeks, count the colonies under a microscope.

Discussion

Our feeder- and xeno-free defined induction method offers a precise and cost-effective platform to induce HE cells in a scalable manner. The faithful formation of hemogenic endothelium in conventional protocols^{10,11,12,13,14} have been hampered by lack of precise control of PSC colony density and size, which affects efficiency of morphogen/cytokine-based directed differentiation. We had experienced inconsistency of hemogenic endothelium induction in each independent batch from conventional protocols. The new protocol enables tight regulation of PSC colony density and size, thus overcomes the inconsistency of hemogenic endothelium induction.

We exploited the uniformed formation of spheroids and subsequently conveyed a feeder- and xeno-free defined condition to form HE in a total of 4 days. We confirmed using three independent cell lines that the spheroid formation assures the consistent formation of HE cells. As a representative result, the 409B2 cell lines yielded 12.7%-23.6% CD34⁺ cell efficiency based on three independent experiments. The critical factor to tile PSC spheroids is LM511-E8. We do not recommend substituting this with other matrix, such as Matrigel or full-length laminin products in our experiences. We experienced that mesodermal organoids were easily detached from Matrigel and lost during differentiation process. And neither Matrigel or full-length laminin do not anchor cells without pre-coating.

The potential limitation of this protocol is that we depend on PSC maintenance medium to maintain PSCs. We have tested other media such as StemFit, but we compromised hemogenic induction. Presumably cells were resistant to exit from pluripotent state in our short time (4 days) induction protocol. If one maintains PSCs in other media, we recommend adapting cells in PSC maintenance medium and conduct a couple of passages prior to differentiation. This platform will allow the systematic manipulation and analysis of cells, and the off-the-shelf production and large-scale induction of hematopoietic cells for potential clinical use. A long-term goal of this system is to model immunodeficiency diseases in humanized mouse models to investigate the responsible cellular and molecular mechanisms and conduct drug screenings.

Materials

Name	Company	Catalog Number	Comments
0.5 M EDTA	Thermo Fisher Scientific	15575	0.5M EDTA
40 μm cell strainer	Corning	352340	40μM cell strainer
6 well plate	Corning	353046	6 well plate
Antibiotic-antimycotic	Thermo Fisher Scientific	15240-112	Penicillin/ Streptomycin/Amphotericin B
anti-CD34 antibody	Beckman Coulter	A07776	anti-CD34 antibody
anti-CD45 antibody	Biolegend	304012	anti-CD45 antibody
BMP4	R&D Systems	314-BP-010	BMP4
CD34 microbeads	Miltenyi	130-046-703	CD34 microbeads
CHIR99021	Wako	038-23101	CHIR99021
Essential 6	Thermo Fisher Scientific	A15165-01	Hemogenic basal medium
Essential 8	Thermo Fisher Scientific	A15169-01	Mesodermal basal medium
Ezsphere SP Microplate 96well	AGC	4860-900SP	micro-fabricated plastic vessel
FCS	Biosera	FB-1365/500	FCS
Fibronectin	Millipore	FC010-100MG	Fibronectin
Flt-3L	R&D Systems	308-FK-005	Flt-3L
Glutamax	Thermo Fisher Scientific	35050-061	L-Glutamine
IL-6/IL-6Rα	R&D Systems	8954-SR	IL-6/IL-6Rα
iMatrix-511	Matrixome	892 001	LM511-E8
ITS-X	Thermo Fisher Scientific	51500-056	Insulin-Transferrin-Selenium-Ethanolamine
MACS buffer	Miltenyi	130-091-221	magnetic separation buffer
Methocult 4435MethoCult™ H4435 Enriched	STEMCELL TECHNOLOGIES	04435	Methylcellulose-based media
mTeSR1	STEMCELL TECHNOLOGIES	85850	PSC maintenance medium
PBS	nacalai tesque	14249-24	PBS
SB431542	Wako	031-24291	SB431542
SCF	R&D Systems	255-SC-010	SCF
Stemline Ⅱ Hematopoietic Stem Cell Expansion Medium	Sigma Aldrich	S0192-500ML	Hematopoietic basal medium
TPO	R&D Systems	288-TPN	TPO
TrypLE Express	Thermo Fisher Scientific	12604-021	dissociation solution
VEGF	R&D Systems	293-VE-010	VEGF
Y-27632	Wako	253-00513	Y-27632